Proactive Investors - Run By Investors For Investors

MaxCyte appoints Infinity Pharma's Claudio Dansky Ullmann as its chief medical officer

Ullmann was most recently the senior vice president and head of clinical development at Infinity Pharmaceuticals Inc, where he oversaw all clinical development and operations
agreement
MaxCyte said Ullmann will be responsible for overseeing clinical development of MaxCyte’s CARMA drug development program

MaxCyte Inc (LON:MXCT) has announced the appointment of Claudio Dansky Ullmann as its chief medical officer, as the firm prepares for clinical testing of its first cell therapy drug candidate.

The AIM-listed company said in his new role, Ullmann will be responsible for overseeing clinical development of MaxCyte’s CARMA drug development program, with the company’s first candidate, MCY-M11, is expected to enter the clinic this year.

READ: MaxCyte reports strong growth in cash and total assets in 2017 as revenues increase by 14%

The global cell-based medicines and life sciences company said Ullmann brings more than 25 years of experience in clinical oncology and drug development.

He was most recently the senior vice president and head of clinical development at Infinity Pharmaceuticals, where he oversaw all clinical development and operations, shaped corporate strategy and was directly involved in business development activities.

He also worked at the Cancer Therapy Evaluation Program of the National Cancer Institute (NCI) and held research roles at the National Institute of Health.

Doug Doerfler, MaxCyte’s CEO, said: “His broad experience in cancer therapy drug development will be invaluable at this stage in MaxCyte’s evolution form a cell engineering technology company to a drug developer with a pipeline of CARMA drug candidate programs.”

The CEO added: “Furthermore, with his deep understanding of the development of immune-oncology therapies and other cancer treatments, Claudio will help us to advance our Flow Electroporation technology to enable our partners to make important medical.

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY TO US PERSONS, AS DEFINED IN REGULATIONS PROMULGATED UNDER THE US SECURITIES ACT 1933, AS AMENDED (THE “US SECURITIES ACT”), OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR PUBLICATION WOULD BE UNLAWFUL.”
View full MXCT profile View Profile

MaxCyte Timeline

Video
November 13 2018
Article
October 10 2018

Related Articles

scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019
Cyrptocurrencies
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
man and woman working in a lab
October 11 2018
There were no adverse safety findings and excellent drug-like properties were confirmed.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use